Takayuki Sugiyama
Overview
Explore the profile of Takayuki Sugiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, et al.
Int J Clin Oncol
. 2024 Dec;
30(3):551-558.
PMID: 39688742
Background: In Japan, since 2014, new treatments such as androgen receptor signaling inhibitors and cabazitaxel have become applicable for metastatic castration-resistant prostate cancer (mCRPC), leading to dramatic changes in treatment...
2.
Baumstark A, Pleus S, Mende J, Jendrike N, Tesar M, Schauer S, et al.
J Diabetes Sci Technol
. 2024 Feb;
:19322968241231294.
PMID: 38361370
Background: Reliable blood glucose (BG) measurements are important for people with diabetes to manage their therapy as well as in point-of-care testing (POCT) performed by health care professionals to monitor...
3.
Watanabe H, Matsushita Y, Tamura K, Motoyama D, Sugiyama T, Otsuka A, et al.
Sci Rep
. 2023 Jul;
13(1):11361.
PMID: 37443122
Recently, several types of systemic therapy using tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) have been performed for advanced renal cell carcinoma (aRCC) patients; however, the optimal strategy...
4.
Sato R, Inamoto T, Matsushita Y, Takemura A, Uchimoto T, Sano A, et al.
Int J Urol
. 2022 Dec;
30(9):730-736.
PMID: 36575640
Objectives: The present study comprehensively investigated the significance of several factors reflecting the therapeutic effects of anticancer treatment on overall survival (OS) in advanced urothelial cancer (UC) patients receiving sequential...
5.
Watanabe K, Otsuka A, Sano A, Sato R, Matsushita Y, Watanabe H, et al.
Int J Urol
. 2022 Dec;
30(1):57-61.
PMID: 36513615
Objectives: To assess the postoperative status of clinically localized prostate cancer patients who underwent robot-assisted radical prostatectomy (RARP) with a focus on de novo overactive bladder (OAB). Methods: The present...
6.
Sato R, Sano A, Watanabe K, Matsushita Y, Watanabe H, Tamura K, et al.
In Vivo
. 2022 Oct;
36(6):2960-2964.
PMID: 36309353
Background/aim: Sexual function in patients with benign prostatic hyperplasia (BPH) could be affected by surgical intervention, such as holmium laser enucleation of the prostate (HoLEP). The objective of the present...
7.
Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H
Int J Urol
. 2022 Jun;
29(9):1026-1030.
PMID: 35669994
Objectives: It has been well documented that partial nephrectomy for completely endophytic renal tumors is a highly challenging procedure accompanied by several technical difficulties even with the assistance of a...
8.
Yamaguchi T, Sugiyama Y, Tanaka T, Kimura T, Yumura Y, Nakano M, et al.
Int J Urol
. 2022 Jun;
29(8):780-792.
PMID: 35643932
Penile cancer is a rare cancer for which no medical guidelines have been established before in Japan. These guidelines aim to standardize, as much as possible, the therapeutic modality for...
9.
Takase T, Tsugawa N, Sugiyama T, Ikesue H, Eto M, Hashida T, et al.
Clin Nutr ESPEN
. 2022 May;
49:256-263.
PMID: 35623823
Background And Aims: Despite reports on the impact of vitamin D status on coronavirus disease 2019 (COVID-19) severity, the association between low vitamin D status and severe COVID-19 remains unclear....
10.
Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H
IJU Case Rep
. 2022 May;
5(3):145-148.
PMID: 35509774
Introduction: Open surgical approach remains the standard treatment for renal cell carcinoma with an inferior vena cava tumor thrombus. In recent years, however, robot-assisted radical nephrectomy and inferior vena cava...